Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

1. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies. We aimed to confirm these findings in an adequately powered randomized trial.We performed a 3 × 2 partial factorial double-blind trial of 17,598 participants

Full Text available with Trip Pro

2019 EvidenceUpdates

2. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. (PubMed)

Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. To estimate all cause mortality and cause specific mortality among patients taking proton pump inhibitors (PPIs).Longitudinal observational cohort study.US Department of Veterans Affairs.New users of PPIs (n=157 625) or H2 blockers (n=56 842).All cause mortality and cause specific mortality associated with taking PPIs (values reported as number of attributable

2019 BMJ

3. Trends in utilization of proton pump inhibitors in British Columbia

Trends in utilization of proton pump inhibitors in British Columbia Trends in utilization of proton pump inhibitors in British Columbia February - March 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 118 T he first three Therapeutics Letters focused on com - plaints related (...) to the upper gastrointestinal tract, a common presentation to the primary care physi- cian. 1-3 These Letters reviewed evidence about H 2 -block- ers, eradication of Helicobacter pylori, and drugs used for gastroesophageal reflux. However, they also raised concerns about chronic acid suppression by daily dosing of omeprazole, the first proton pump inhibitor (PPI) on the Canadian market. By 1994 there was already concern that long-term proton pump inhibition could be problem- atic. Since

2019 Therapeutics Letter

4. Proton pump inhibitors: increased mortality

Proton pump inhibitors: increased mortality Prescrire IN ENGLISH - Spotlight ''Proton pump inhibitors: increased mortality'', 1 January 2019 {1} {1} {1} | | > > > Proton pump inhibitors: increased mortality Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Proton pump inhibitors: increased mortality FEATURED REVIEW Proton pump inhibitors (PPIs (...) ) such as omeprazole are used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. PPIs have few severe adverse effects in the short term. But this is not the case in the long term. Full review (3 pages) available for download by subscribers. Abstract Proton pump inhibitors (PPIs) are widely used in oesophagitis, gastroesophageal reflux disease and peptic ulcer disease. They provoke few severe adverse effects in the short term, but this is not the case in the long term (infections, fractures

2019 Prescrire

5. Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication

Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 1 Editorial Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor T reatment (...) and Gastric Cancer after Helicobacter pylori Eradication A recent paper by Cheung et al. (1) reported that long-term use of proton pump inhibitors (PPIs) was associated with an increased risk of gastric cancer “even after” Helicobacter pylori (H. pylori) eradication. This has created significant concerns among physicians and patients (2). The Canadian Association of Gastroenterology (CAG) has serious reservations about the validity of this study and, hence, considers it important to provide guidance

2019 Canadian Association of Gastroenterology

6. Reassessing the use of proton pump inhibitors and histamine-2 antagonists in critically ill children: a systematic review and meta-analysis

Reassessing the use of proton pump inhibitors and histamine-2 antagonists in critically ill children: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

7. Proton pump inhibitor therapy and the risk of hepatic encephalopathy in cirrhotic patients

Proton pump inhibitor therapy and the risk of hepatic encephalopathy in cirrhotic patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

8. The impact of proton pump inhibitor use on the incidence of cancer: a protocol for a systematic review and meta-analysis

The impact of proton pump inhibitor use on the incidence of cancer: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

9. The efficacy and safety of proton pump inhibitors and amoxicillin-containing high dose dual therapy for Helicobacter pylori infection

The efficacy and safety of proton pump inhibitors and amoxicillin-containing high dose dual therapy for Helicobacter pylori infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

10. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis

Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. The efficacy of proton pump inhibitors and histamine 2 receptor antagonists in children with asthma: a systematic review and meta-analysis of randomized controlled trials

The efficacy of proton pump inhibitors and histamine 2 receptor antagonists in children with asthma: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

12. The effectiveness of proton pump inhibitors versus histamine-2-receptor antagonists for stress ulcer prophylaxis in critically ill patients: comparison of randomized trials with cohort studies

The effectiveness of proton pump inhibitors versus histamine-2-receptor antagonists for stress ulcer prophylaxis in critically ill patients: comparison of randomized trials with cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

13. Effect of proton pump inhibitor on bone mineral density: a systematic review and meta-analysis of observational studies

Effect of proton pump inhibitor on bone mineral density: a systematic review and meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

14. Efficacy and safety of potassium-competitive acid blocker versus proton pump inhibitor for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis

Efficacy and safety of potassium-competitive acid blocker versus proton pump inhibitor for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

15. Proton pump inhibitors use during pregnancy

Proton pump inhibitors use during pregnancy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

16. Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy [Cochrane protocol]

Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

17. Proton pump inhibitors for chronic obstructive pulmonary disease [Cochrane protocol]

Proton pump inhibitors for chronic obstructive pulmonary disease [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

18. Proton pump inhibitor and its association with gastroesophageal variceal hemorrhage: a meta-analysis

Proton pump inhibitor and its association with gastroesophageal variceal hemorrhage: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

19. Advantages and disadvantages of proton pump inhibitor use: an umbrella review of systematic reviews and meta-analyses

Advantages and disadvantages of proton pump inhibitor use: an umbrella review of systematic reviews and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

20. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. (PubMed)

Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. Anticoagulant choice and proton pump inhibitor (PPI) cotherapy could affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment.To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants with and without PPI

2018 JAMA